SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,698,870 | -48.8% | 1,005,776 | +17.0% | 1.96% | -40.0% |
Q2 2023 | $40,414,489 | +12.1% | 859,517 | 0.0% | 3.26% | +9.3% |
Q1 2023 | $36,065,333 | +10.4% | 859,517 | +0.4% | 2.99% | +7.3% |
Q4 2022 | $32,667,558 | -2.0% | 856,517 | +0.6% | 2.78% | +5.7% |
Q3 2022 | $33,341,000 | +21.2% | 851,409 | 0.0% | 2.64% | +10.0% |
Q2 2022 | $27,501,000 | -2.5% | 851,409 | -0.0% | 2.40% | +10.0% |
Q1 2022 | $28,192,000 | -15.2% | 851,719 | +9.0% | 2.18% | +2.6% |
Q4 2021 | $33,255,000 | +21.5% | 781,730 | +26.5% | 2.12% | +28.6% |
Q3 2021 | $27,380,000 | -19.7% | 617,930 | +2.9% | 1.65% | -12.1% |
Q2 2021 | $34,114,000 | -24.1% | 600,500 | 0.0% | 1.88% | -26.6% |
Q1 2021 | $44,947,000 | -12.0% | 600,500 | +1.7% | 2.56% | -4.3% |
Q4 2020 | $51,058,000 | +41.5% | 590,200 | 0.0% | 2.68% | +35.2% |
Q3 2020 | $36,073,000 | +50.8% | 590,200 | +2.6% | 1.98% | +37.9% |
Q2 2020 | $23,917,000 | +41.9% | 575,200 | -2.0% | 1.44% | +1.8% |
Q1 2020 | $16,849,000 | -64.3% | 586,674 | -10.2% | 1.41% | -45.7% |
Q4 2019 | $47,183,000 | -50.6% | 653,594 | -4.0% | 2.60% | -59.2% |
Q3 2019 | $95,523,000 | -34.4% | 680,894 | -14.4% | 6.36% | -10.1% |
Q2 2019 | $145,562,000 | +6.7% | 795,031 | -7.3% | 7.08% | +24.4% |
Q1 2019 | $136,414,000 | +67.3% | 857,681 | +0.8% | 5.69% | +31.2% |
Q4 2018 | $81,515,000 | -31.3% | 850,977 | +1.3% | 4.34% | -9.6% |
Q3 2018 | $118,703,000 | -8.9% | 840,372 | +0.9% | 4.80% | -7.9% |
Q2 2018 | $130,317,000 | -1.1% | 832,536 | +1.7% | 5.21% | -7.6% |
Q1 2018 | $131,809,000 | -1.3% | 818,331 | +0.9% | 5.64% | -2.0% |
Q4 2017 | $133,548,000 | +172.3% | 810,806 | +3.0% | 5.75% | +178.4% |
Q3 2017 | $49,046,000 | -40.4% | 787,251 | -23.8% | 2.07% | -46.2% |
Q2 2017 | $82,270,000 | +5.0% | 1,033,025 | -6.3% | 3.84% | +3.8% |
Q1 2017 | $78,316,000 | +51.9% | 1,101,951 | +9.1% | 3.70% | +25.8% |
Q4 2016 | $51,567,000 | +24.1% | 1,009,930 | +12.0% | 2.94% | +21.9% |
Q3 2016 | $41,539,000 | +229.9% | 902,051 | +115.9% | 2.41% | +153.7% |
Q2 2016 | $12,591,000 | – | 417,878 | – | 0.95% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |